Evidence

The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer

August 26, 2014

PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 August 2014). AUTHORS: R. Exner, Z. Bago-Horvath, R. Bartsch, M. Mittlboeck, V.P. Retèl, F. Fitzal, M. Rudas, C. Singer, G. Pfeiler, M. Gnant, R. Jakesz, P. Dubsky SUMMARY: According to MammaPrint (MP), 76% were low risk. In over a third of patients, discordance between clinical and molecular risk…

Read more

Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature

December 7, 2010

PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van’t Veer SUMMARY: Pooled analysis: In the group of 89 chemotherapy-naive patients, after a median follow-up of 7.4 years, 35 (39%) distant recurrences and 29 (33%) breast…

Read more